Your session is about to expire
← Back to Search
Doxycycline for Sexually Transmitted Infections
Study Summary
This trial will investigate the efficacy of STI PrEP and STI PEP to reduce bacterial STIs in gbMSM, and address the rising epidemic of bacterial STIs in Canada.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 22 Patients • NCT05399290Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to doxycycline or tetracyclines.I plan to be sexually active with multiple male partners this year.I had syphilis, gonorrhea, or chlamydia treated in the last year.I have had sexual activity with more than one male partner in the last year.I am capable of becoming pregnant.I am currently taking isotretinoin.I am currently taking tetracycline or doxycycline regularly.I am not taking medications like barbiturates, phenytoin, or carbamazepine.I am a man aged 18 or older.
- Group 1: STI PrEP arm
- Group 2: STI PEP arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Approved for 60 Other Conditions - This treatment demonstrated efficacy for 60 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there a minimal risk associated with utilizing the sexually transmitted infection post-exposure prophylaxis protocol?
"Due to the Phase 4 status of this prophylactic treatment, our team at Power rated its safety as a 3 on their scale."
How many people are included in this clinical experiment?
"Affirmative. Clinicaltrials.gov shows that this clinical trial was publicly announced on June 2nd, 2023 and is currently looking for 560 participants from 1 separate medical facility."
Are there presently any vacancies for participants in this research project?
"According to clinicatrials.gov, recruitment is currently underway for this study which was originally listed on June 2nd 2023 and had its most recent update posted a few weeks later on the 26th of June."
In what situations is STD post-exposure prophylaxis typically prescribed?
"Severe acne can be managed with STI PEP arm. Additionally, this medication has been found to address other medical issues such as trachoma, disease and klebsiella infections."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger